A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
← catalyst calendarNCT06435429 · readout in 618 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
550estimated
Sites
166
Countries
Australia, Austria, Belgium +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-13 | actual | When the study began enrolling |
| Primary completion | 2028-04-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-10-18 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic HER2-positive Breast Cancer
Interventions
- Drug: Zanidatamab
- Drug: Trastuzumab
- Drug: Eribulin
- Drug: Vinorelbine
- Drug: Gemcitabine
- Drug: Capecitabine
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)
measured Until disease progression or death, up to approximately 44 months
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed